Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
THOUSAND OAKS, Calif., May 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 38<
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
- Fastest growing Top 10 pharmaceutical business in the U.S., Europe & Japan in 2012
NEW BRUNSWICK, N.J.,
Clinical trial tests targeting prostate cancer treatment
Study to evaluate whether drug works better against tumors with specific genetic anomaly
ANN ARBOR, Mich.,
Zensun Announces Positive Clinical Results for Neucardin™ to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients
Clinical program supports accelerated approval filing with CFDA in China, and a Phase 3 program in the U.S.
SAN DIEGO and
NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
NW Bio Exhibit Will Describe DCVax Technology and Clinical Trial Progress at Annual Meeting of Over 25,000 Oncologists
BETHESDA, Md.
Forest Laboratories Provides Update on Succession Planning
Forest Laboratories Provides Update on Succession Planning
Howard Solomon to Retire as CEO and President at End of 2013; Will Serve as Chairman to 2014 AGM and Then Become Chairman Emeritus...
Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives Tokyo, Japan (May 22, 2013) – Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo...
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 - Fastest growing Top 10 pharmaceutical business in the U.S.,...
Amgen Announces Voting Results of Annual Meeting of Stockholders
THOUSAND OAKS, Calif., May 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from t
Abbott to Present at Deutsche Bank 38th Annual Health Care Conference
ABBOTT PARK, Ill., May 22, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Deutsche Bank 38th Annual Health Care Co
Pfizer Announces Plan for Split-Off of Zoetis
Pfizer Announces Plan for Split-Off of Zoetis
Provides Pfizer shareholders an option for a tax-free exchange Better positions Pfizer to focus on its core business as an innovative...
Merck Announces $5 Billion Accelerated Share Repurchase
Merck Announces $5 Billion Accelerated Share Repurchase Tuesday, May 21, 2013 5:00 pm EDT
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United...
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
- XIENCE Xpedition™ 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents
ABBOTT PARK, Ill., May 21,
Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
Regulatory News :
Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million
Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million Xellia is a leading developer and manufacturer of anti-infective therapies for multi-drug resistant infections. With this acquisition Novo...
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
— EMA Submission Planned in the Coming Weeks —
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
Video shows how those from the medical field bring patient care experience to pharmaceutical career
INDIANAPOLIS,
Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
Symptom improvements in-line with effects reported with stimulant drugs
LOS ANGELES, May 20, 2013 /P
UK calls for international action on antimicrobial resistance
UK calls for international action on antimicrobial resistance Health Secretary Jeremy Hunt and Chief Medical Officer (CMO) Professor Dame Sally Davies are leading a delegation to the World Health...
